Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board  >  Aeolus Pharmaceuticals, Inc.    AOLS

AEOLUS PHARMACEUTICALS, INC.

(AOLS)
My previous session
Most popular
  Report  
SummaryNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Aeolus Pharmaceuticals, Inc. : Aeolus Announces Commencement of Assignment for the Benefit of Creditors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/23/2018 | 04:31pm EDT

MISSION VIEJO, CA / ACCESSWIRE / March 23, 2018 / Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), announced today that it has commenced an out-of-court liquidation conducted by an Assignment for the Benefit of Creditors pursuant to Delaware law. The Board of Directors has authorized Aeolus to enter into a General Assignment agreement with John D. McLaughlin, Jr., Esq. as the Assignee of all of Aeolus' remaining assets. To this effect, Aeolus has transferred its assets to the Assignee whose contractual duty is to liquidate these assets and distribute any proceeds to creditors. If the recovered value of these assets is not greater than the liabilities of Aeolus, there will not be any residual value for stockholders. In connection with the Assignment, Aeolus will discontinue the development of its compounds and all other operations.

About Aeolus Pharmaceuticals

Aeolus Pharmaceuticals, based in Mission Viejo, CA, has been engaged in the development of medical countermeasures for radiological, chemical and biological threats under programs previously supported by funding from the United States government.

Forward-Looking Statements

The statements in this press release that are not purely statements of historical fact are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements herein with respect to the Company's plans and the successful execution of the Company's current strategy. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.

Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' Annual Report on Form 10-K for the year ended September 30, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Contact:

John McManus
President and Chief Executive Officer
Aeolus Pharmaceuticals, Inc.
1-(949) 481-9820

SOURCE: Aeolus Pharmaceuticals, Inc.


© Accesswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AEOLUS PHARMACEUTICALS, IN
2017AEOLUS PHARMACEUTICALS : Receives BARDA Decision Regarding Additional Options fo..
PU
2017AEOLUS PHARMACEUTICALS : Announces First Quarter 2017 Financial Results
PU
2016AEOLUS PHARMACEUTICALS : Announces Publication of Additional Data Demonstrating ..
PU
2016STOCKNEWSNOW.COM : Publishes New SNNLive Video Interview with Aeolus Pharmaceuti..
PR
2016AEOLUS PHARMACEUTICALS : Announces Second Quarter Fiscal Year 2016 Financial Res..
PU
2014AEOLUS PHARMACEUTICALS : Files Investigational New Drug Application With US Food..
MW
2014AEOLUS PHARMACEUTICALS : Announces Third Quarter Fiscal Year 2014 Financial Resu..
MW
2014AEOLUS PHARMACEUTICALS : Announces Additional Data Demonstrating Efficacy of AEO..
MW
2014AEOLUS PHARMACEUTICALS : Announces Publication of Data Demonstrating Efficacy of..
MW
2014AEOLUS PHARMACEUTICALS : Pharmateucticals to Present at LD Micro Invitational Co..
MW
More news
Chart AEOLUS PHARMACEUTICALS, INC.
Duration : Period :
Aeolus Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
John L. McManus President & Chief Executive Officer
David C. Cavalier Chairman, Chief Financial Officer & Secretary
Christopher Stanley Vice President-Operations
Amit Kumar Independent Director
Chris A. Rallis Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AEOLUS PHARMACEUTICALS, INC.0
CSL LIMITED6.50%63 534
BIOGEN-27.98%42 629
ALEXION PHARMACEUTICALS33.74%29 098
SAMSUNG BIOLOGICS CO LTD--.--%19 732
GRIFOLS2.53%16 228